Chemoradiotherapy for limited-stage small-cell lung cancer and interstitial lung abnormalities

Abstract Background Patients with lung cancer and interstitial disease treated radiotherapy are at risk of developing radiation pneumonitis. However, the association between abnormalities (ILAs) pneumonitis in patients limited-stage small-cell (LS-SCLC) remains unclear. Furthermore, prognosis is uncertain for SCLC ILAs chemoradiotherapy. We investigated impact on assessed LS-SCLC Methods retrospectively reviewed medical records 149 who received first-line treatment January 2009 December 2016. Results In univariate analysis, showed a higher incidence rate compared those without (64% vs. 10%, P < 0.001). Multivariate analysis confirmed that were significantly associated poorer overall survival than (median, 18.9 67.9 months, = 0.0338). significant independent negative prognostic factor. 2-year 5-year rates chemoradiotherapy 36% 26%, respectively, 8% 0%, chemotherapy alone. Conclusions found to be predictive factor had both possibility long-term